IQVIA (IQV) Scheduled to Post Quarterly Earnings on Thursday

IQVIA (NYSE:IQV) will issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $2.19 per share for the quarter. IQVIA has set its FY24 guidance at $10.95-11.25 EPS and its FY 2024 guidance at 10.950-11.250 EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. The firm had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the business posted $2.54 earnings per share. On average, analysts expect IQVIA to post $10 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IQVIA Stock Up 0.3 %

Shares of NYSE:IQV opened at $235.48 on Tuesday. The company’s fifty day moving average is $245.21 and its 200-day moving average is $223.56. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a market capitalization of $42.74 billion, a PE ratio of 32.30, a P/E/G ratio of 2.27 and a beta of 1.50.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on IQV shares. SVB Leerink assumed coverage on shares of IQVIA in a research report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price target on the stock. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Truist Financial increased their price objective on shares of IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, Barclays raised their price target on shares of IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $256.80.

Insider Activity

In related news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock worth $10,331,003 over the last quarter. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.